News & Updates

Print this page Facebook Twitter Google+ Email

The Phamarceutical Benefits Advisory Committee has recommended the listing of tenofovir alafenamide (TAF) for the treatment of chronic hepatitis B.

The Therapeutic Goods Administration (TGA) has warned that direct-acting antiviral (DAA) medicines for the treatment of chronic hepatitis C virus (HCV) infection have been associated with reactivation of hepatitis B virus (HBV) in people with a current or previous HBV infection.

The Pharmaceutical Benefits Scheme (PBS) and the Gastroenterological Society of Australia (GESA) have published information for health professionals to help them manage the new hepatitis C treatments. This includes national guidelines for the management of hepatitis C based on a consensus statement first published in 2016.

This statement was prepared by an expert panel representing the Gastroenterological Society of Australia (Australian Liver Association), the Australasian Society for Infectious Diseases, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Australasian Hepatology Association, Hepatitis Australia and the Royal Australian College of General Practitioners.

The recommendations are updated regularly as new medicines become available.

The links below have been updated to include the new hepatitis C treatment consensus guidelines from September 2018.

It seems a bit trite to say that a happier lifestyle will increase the chances of stronger health. How do we actually break this down into achievable steps?

The Gastroenterological Society of Australia (GESA) have published a January 2017 update of the hepatitis C virus infection consensus statement.

South Australian hepatitis B community education projects are but a small selection of the 40 projects progressively being implemented Australia-wide.

As Australians with hepatitis C are being cured at unprecedented rates, those living with hepatitis B are looking forward to a new treatment which promises the same efficacy as current drugs but with less toxic side effects.

The Australian Medical Association (AMA) has called for clean needle programs to be introduced in prisons to protect both staff and inmates and reduce the spread of blood borne viruses.

Highlights - Hepatitis B Community Education, Hep B treatment uptake in SA, Celebrations with the Big Issue, LiveR Life comes to SA, AMA calls for needle exchange program in prisons

Another hepatitis C treatment option has been added to the Pharmaceutical Benefits Scheme (PBS).

Hepatitis SA's Singing O'livers send greetings in 40 degree heat...

The Pharmaceutical Benefits Advisory Committee (PBAC) has given positive recommendations for PBS listing for more hepatitis C direct-acting antiviral drugs.

Search Hepatitis SA